Blocking the CXCL1-CXCR2 axis enhances the effects of doxorubicin in HCC by remodelling the tumour microenvironment via the NF-kappa B/IL-1 beta/CXCL1 signalling pathway

Inflammation is a core mechanism for oncogenesis. Chemokines act as important mediators of chronic inflammation and the tumour inflammatory response. However, there is limited information on chemokines in hepatocellular carcinoma (HCC), a disease for which almost all cases are derived from chronic liver inflammation. Here, we explored the protumor effects of CXCL1, a commonly elevated inflammatory chemokine in cirrhosis, in HCC. The protumor role was confirmed in clinical samples from HCC patients. CXCL1 enhanced tumorigenesis in the hepatic inflammatory microenvironment directly by acting on tumour cells and indirectly through promoting the recruitment of macrophages. The increase in the number of macrophages in the tumour microenvironment (TME) promoted tumour cell epithelial-mesenchymal transition (EMT) and significantly increased CXCL1 levels in the TME partly through NF-kappa B/IL-1 beta activation. To investigate the potential therapeutic value of CXCL1 in HCC with an inflammatory background, an antibody blocking CXCL1 was used alone or combined with the chemotherapy agent doxorubicin (DOX), with the goal of reshaping the TME. It has been shown that blocking CXCL1-CXCR2 inhibits tumour progression and reduces macrophage recruitment in the TME. The combination regimen has been shown to synergistically reduce the number of pro-tumour macrophages in the TME and suppress tumour progression. This provides insight into therapeutic strategies for treating HCC patients with high CXCL1 expression.

Automated summary

Inflammation is a core mechanism for oncogenesis, and chemokines play important roles in chronic inflammation and the tumour inflammatory response. This study investigates the protumor effects of CXCL1 in hepatocellular carcinoma (HCC), a disease derived from chronic liver inflammation. CXCL1 enhances tumorigenesis through direct effects on tumour cells and indirectly by promoting the recruitment of macrophages. Blocking CXCL1-CXCR2 inhibits tumour progression and reduces macrophage recruitment in the tumour microenvironment (TME), showing therapeutic potential for HCC patients with high CXCL1 expression.